A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Source: Leukemia Research - Category: Hematology Authors: Srdan Verstovsek, Ruben A. Mesa, Mohamed E. Salama, Li Li, Celine Pitou, Fabio P. Nunes, Gregory L. Price, Jennifer L. Giles, Deborah N. D ’Souza, Richard A. Walgren, Josef T. Prchal Tags: Research paper Source Type: research